These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21109690)

  • 21. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
    Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
    Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
    Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
    Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
    Ximeri M; Galanopoulos A; Klaus M; Parcharidou A; Giannikou K; Psyllaki M; Symeonidis A; Pappa V; Kartasis Z; Liapi D; Hatzimichael E; Kokoris S; Korkolopoulou P; Sambani C; Pontikoglou C; Papadaki HA;
    Haematologica; 2010 Mar; 95(3):406-14. PubMed ID: 19773257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
    Azaceta G; Calasanz MJ; Dourdil V; Bonafonte E; Izquierdo I; Palomera L
    Leuk Lymphoma; 2010 Oct; 51(10):1941-3. PubMed ID: 20846100
    [No Abstract]   [Full Text] [Related]  

  • 26. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
    Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
    Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
    [No Abstract]   [Full Text] [Related]  

  • 27. Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
    Syed YY; Scott LJ
    Drugs; 2013 Jul; 73(11):1183-96. PubMed ID: 23824699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Elderly patients with myelodysplastic syndrome with del 5q receiving lenalidomide: two case reports with poor prognosis].
    Reibel F; Debord C; Bouhadiba S; Chaïbi P; Bilhou-Nabera C; Le Garff M; Gouin-Thibault I; Siguret V
    Ann Biol Clin (Paris); 2010; 68(2):248-53. PubMed ID: 20348054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
    Vozella F; Latagliata R; Carmosino I; Volpicelli P; Montagna C; Romano A; Roberto A; Finsinger P; Mancini M; Breccia M; Oliva E; Oliva E
    Hematol Oncol; 2015 Mar; 33(1):48-51. PubMed ID: 25950027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
    Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
    Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
    Mallo M; Del Rey M; Ibáñez M; Calasanz MJ; Arenillas L; Larráyoz MJ; Pedro C; Jerez A; Maciejewski J; Costa D; Nomdedeu M; Diez-Campelo M; Lumbreras E; González-Martínez T; Marugán I; Such E; Cervera J; Cigudosa JC; Alvarez S; Florensa L; Hernández JM; Solé F
    Br J Haematol; 2013 Jul; 162(1):74-86. PubMed ID: 23614682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.
    Giagounidis A; Fenaux P; Mufti GJ; Muus P; Platzbecker U; Sanz G; Cripe L; Von Lilienfeld-Toal M; Wells RA
    Ann Hematol; 2008 May; 87(5):345-52. PubMed ID: 18265982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
    Talati C; Sallman D; List A
    Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.
    Mährle T; Akyüz N; Fuchs P; Bonzanni N; Simnica D; Germing U; Asemissen AM; Jann JC; Nolte F; Hofmann WK; Nowak D; Binder M
    Haematologica; 2019 Jul; 104(7):1355-1364. PubMed ID: 30655375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
    Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
    Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment.
    Scharenberg C; Jansson M; Saft L; Hellström-Lindberg E
    Br J Haematol; 2018 Feb; 180(4):526-533. PubMed ID: 29377069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
    List AF; Baker AF; Green S; Bellamy W
    Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.